Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) is now available.
GenFleet Therapeutics has announced the proposal for adopting the H Share Option Scheme and H Share Incentive Scheme, aimed at providing eligible participants with opportunities to acquire proprietary interests in the company. These schemes are designed to incentivize and retain talent, thereby enhancing the company’s value and aligning the interests of employees and stakeholders. The schemes are subject to shareholder approval and compliance with Hong Kong Stock Exchange listing rules.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a joint stock company incorporated in China, operating in the biotechnology sector. The company focuses on developing innovative therapies and treatments, with a market focus on enhancing the value of its shares for the benefit of its shareholders.
Average Trading Volume: 1,962,660
See more data about 2595 stock on TipRanks’ Stock Analysis page.